Silence Therapeutics plc – NASDAQ:SLN
Silence Therapeutics stock price today
$5.52
-1.58
-22.25%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 5 hours
Silence Therapeutics stock price monthly change
-65.53%
month
Silence Therapeutics stock price quarterly change
-65.53%
quarter
Silence Therapeutics stock price yearly change
-59.82%
year
Silence Therapeutics key metrics
Market Cap | 313.97M |
Enterprise value | 112.90M |
P/E | -3.89 |
EV/Sales | 6.99 |
EV/EBITDA | -2.67 |
Price/Sales | 9.14 |
Price/Book | 4.32 |
PEG ratio | 0.34 |
EPS | -0.92 |
Revenue | 26.40M |
EBITDA | -39.66M |
Income | -34.93M |
Revenue Q/Q | 9.07% |
Revenue Y/Y | 14.05% |
Profit margin | -223.9% |
Oper. margin | -302.76% |
Gross margin | 43.88% |
EBIT margin | -302.76% |
EBITDA margin | -150.21% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSilence Therapeutics stock price history
Silence Therapeutics stock forecast
Silence Therapeutics financial statements
| Jun 2023 | 9.10M | -10.40M | -114.25% |
|---|---|---|---|
| Sep 2023 | 2.79M | -8.25M | -294.85% |
| Dec 2023 | 2.09M | -14.41M | -686.61% |
| Mar 2024 | 12.40M | -1.87M | -15.12% |
| Dec 2023 | 2.09M | -14.41M | -686.61% |
|---|---|---|---|
| Mar 2024 | 12.40M | -1.87M | -15.12% |
| Sep 2025 | 3.43M | -5.95M | -173.3% |
| Dec 2025 | 3.53M | -6.35M | -179.55% |
Analysts Price target
Financials & Ratios estimates
| 2023-11-14 | -0.56 | -0.28 |
|---|---|---|
| 2024-03-13 | -0.25 | -0.47 |
| 2024-05-16 | -0.23 | -0.05 |
| Jun 2023 | 92711000 | 80.45M | 86.78% |
|---|---|---|---|
| Sep 2023 | 97942000 | 77.94M | 79.58% |
| Dec 2023 | 93822000 | 76.77M | 81.83% |
| Mar 2024 | 194379000 | 70.47M | 36.26% |
| Jun 2023 | -14.95M | -4.70M | 3.18M |
|---|---|---|---|
| Sep 2023 | -4.87M | 20.62M | 12.03M |
| Dec 2023 | -11.86M | 382K | 9.92M |
| Mar 2024 | -7.49M | -39.03M | 105.56M |
Silence Therapeutics alternative data
| Aug 2023 | 122 |
|---|---|
| Sep 2023 | 122 |
| Oct 2023 | 122 |
| Nov 2023 | 122 |
| Dec 2023 | 122 |
| Jan 2024 | 122 |
| Feb 2024 | 122 |
| Mar 2024 | 109 |
| Apr 2024 | 109 |
| May 2024 | 109 |
| Jun 2024 | 109 |
| Jul 2024 | 109 |
Silence Therapeutics other data
1.72%
-19.33%
of SLN is owned by hedge funds
1.66M
-17.06M
shares is hold by hedge funds
| Quarter | Transcript |
|---|---|
| Q4 2023 13 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q4 2022 15 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Q4 2021 17 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Q2 2021 12 Aug 2021 | Q2 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Mark Andrew Rothera (1963) Pres, Chief Executive Officer & Executive Director | $702,660 |
Dr. Giles V. Campion M.D. (1954) Executive Vice President, Head of R&D, Chief Medical Officer and Executive Director | $588,030 |
-
What's the price of Silence Therapeutics stock today?
One share of Silence Therapeutics stock can currently be purchased for approximately $5.52.
-
When is Silence Therapeutics's next earnings date?
Unfortunately, Silence Therapeutics's (SLN) next earnings date is currently unknown.
-
Does Silence Therapeutics pay dividends?
No, Silence Therapeutics does not pay dividends.
-
How much money does Silence Therapeutics make?
Silence Therapeutics has a market capitalization of 313.97M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 44.99% to 25.38M US dollars. Silence Therapeutics made a loss 43.27M US dollars in net income (profit) last year or -$0.05 on an earnings per share basis.
-
What is Silence Therapeutics's stock symbol?
Silence Therapeutics plc is traded on the NASDAQ under the ticker symbol "SLN".
-
What is Silence Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Silence Therapeutics?
Shares of Silence Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Silence Therapeutics's key executives?
Silence Therapeutics's management team includes the following people:
- Mr. Mark Andrew Rothera Pres, Chief Executive Officer & Executive Director(age: 62, pay: $702,660)
- Dr. Giles V. Campion M.D. Executive Vice President, Head of R&D, Chief Medical Officer and Executive Director(age: 71, pay: $588,030)
-
How many employees does Silence Therapeutics have?
As Jul 2024, Silence Therapeutics employs 109 workers.
-
When Silence Therapeutics went public?
Silence Therapeutics plc is publicly traded company for more then 4 years since IPO on 8 Sep 2020.
-
What is Silence Therapeutics's official website?
The official website for Silence Therapeutics is silence-therapeutics.com.
-
How can i contact Silence Therapeutics?
Silence Therapeutics can be reached via phone at +44 20 3457 6900.
Silence Therapeutics company profile:
Silence Therapeutics plc
silence-therapeutics.comExchange:
NASDAQ
Full time employees:
109
Industry:
Biotechnology
Sector:
Healthcare
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
72 Hammersmith Road
London, W14 8TH
London, W14 8TH
CIK: 0001479615
ISIN: US82686Q1013
CUSIP: 82686Q101
